Breast Health: Self-Exam, Mammography, Breast Pain, and Cancer Prevention

Introduction

Breast health encompasses awareness of normal breast tissue, self-monitoring for changes, appropriate screening, and evaluation of breast symptoms. Breast cancer is the most common cancer in women worldwide (excluding skin cancer). Understanding normal breast changes throughout the menstrual cycle and lifespan helps distinguish benign from concerning findings.

Breast Anatomy

Structure	Function
Lobules	Milk-producing glands (15-20 per breast)
Ducts	Channels that carry milk to nipple
Nipple-areola complex	Delivery of milk; contains Montgomery glands (lubrication)
Fat (adipose tissue)	Determines breast size and shape
Cooper ligaments	Connective tissue supporting breast structure
Axillary tail (Spence tail)	Breast tissue extending into axilla

Breast Self-Awareness

Clinical Breast Exam vs Self-Exam

Aspect	Breast Self-Exam (BSE)	Clinical Breast Exam (CBE)	Breast Self-Awareness
Performer	Patient	Healthcare provider	Patient
Frequency	Monthly (formerly recommended)	Annually (controversial)	Awareness of normal
Current recommendation	Not recommended for average-risk women	Optional (limited evidence)	Recommended by ACOG
Benefit	May detect interval cancers	May detect cancers between mammograms	Early symptom recognition
Harm	False positives, anxiety, unnecessary biopsies	Similar to BSE	Minimal

Breast Self-Awareness Components

Component	Description
Know normal	Familiarity with usual appearance and feel at different times of cycle
Visual inspection	Look at breasts in mirror (arms at sides, overhead, on hips)
Palpation (optional)	Feel entire breast and axilla while lying down (using pads of fingers in circular pattern)
When to get help	Report new: lump, skin changes, nipple discharge, pain, swelling, dimpling

Breast Pain (Mastalgia)

Types

Type	Prevalence	Pattern	Etiology	Management
Cyclical	70%	Bilateral, outer quadrants, premenstrual, resolves with menses	Hormonal sensitivity of breast tissue	Supportive bra, NSAIDs, evening primrose oil (limited evidence), reduce caffeine (controversial), OCPs
Non-cyclical	30%	Unilateral, constant, unrelated to menstrual cycle	Musculoskeletal (40%), chest wall, trauma, infection, galactorrhea	Treat underlying cause; topical NSAIDs; rule out infection/malignancy
Extramammary	<5%	Referred pain from chest wall, ribs, heart, lungs, esophagus	Costochondritis, GERD, angina, pulmonary embolism	Evaluate source

Red Flags for Breast Pain

Finding	Concern
Focal, persistent, unilateral pain	Breast cancer (rarely presents only with pain; <5% of breast cancers)
Pain + palpable mass	Requires imaging
Pain + skin changes (erythema, peau d’orange)	Inflammatory breast cancer
Pain + fever, warmth, swelling	Mastitis, abscess
Postmenopausal new breast pain	Higher concern (less hormonal influence)

Fibrocystic Changes

Feature	Description
Prevalence	50-60% of reproductive-age women
Age peak	30-50 years
Symptoms	Breast pain, nodularity, lumpiness (especially pre-menstrual)
Pathology	Stromal fibrosis, cyst formation, epithelial hyperplasia (non-proliferative)
Cancer risk	None for non-proliferative changes; mild increase for proliferative with atypia
Management	Reassurance, NSAIDs, supportive bra, caffeine reduction (controversial), OCPs

Common Benign Breast Masses

Mass	Typical Age	Characteristic	Management
Fibroadenoma	15-35	Firm, rubbery, mobile, well-circumscribed; “breast mouse”	US + biopsy if needed; may resolve; surgical excision if growing,>3 cm, or symptomatic
Simple cyst	30-50 (perimenopausal)	Smooth, round, fluid-filled; may be painful	Aspirate if symptomatic or complex features
Complex cyst	Any	Internal echoes, septations, thick wall	Biopsy to rule out malignancy
Intraductal papilloma	35-55	Bloody or serous nipple discharge; subareolar	Surgical excision (risk of atypia/malignancy)
Lipoma	Any	Soft, fatty, benign	Reassurance; excision if symptomatic
Fat necrosis	Post-trauma, radiation, surgery	Firm, irregular, may mimic cancer	Biopsy confirms; no treatment needed
Mastitis/abscess	Lactating (90%); any	Pain, erythema, warmth, fever	Antibiotics + drainage if abscess
Duct ectasia	Perimenopausal	Thick, green/brown nipple discharge; dilated ducts	Warm compresses; antibiotics if infected; duct excision if persistent
Hamartoma	Any	Well-circumscribed mass with mixed tissue	Benign; excision if symptomatic

Nipple Discharge

Finding	Benign (Likely)	Concerning (Rule Out Malignancy)
Color	Milky (galactorrhea), green, brown, yellow	Clear, watery, pink, bloody
Spontaneity	Expressible only	Spontaneous (no squeezing)
Unilateral vs bilateral	Usually bilateral (except infection)	Usually unilateral
Duct involvement	Multiple ducts	Single duct
Associated mass	No	Yes
Cytology	Not needed	Biopsy of underlying lesion

Galactorrhea (Milky Nipple Discharge)

Cause	Evaluation	Treatment
Pregnancy/lactation	hCG	N/A
Prolactinoma	Serum prolactin, MRI pituitary	Dopamine agonist (cabergoline, bromocriptine)
Hypothyroidism	TSH	Thyroid hormone replacement
Medications	Review: antipsychotics, SSRIs, OCPs, opioids, H2 blockers, verapamil	Discontinue or change medication
Chest wall irritation	History of trauma, surgery, herpes zoster	Treat underlying cause
Idiopathic	Rule out other causes	Reassurance

Mammography

Screening Guidelines

Organization	Age to Start	Interval	Age to Stop
ACS (American Cancer Society)	45 (optional 40-44)	Annual (45-54); Q2 years (55+)	Life expectancy <10 years
USPSTF (2024 draft)	40	Every other year	Age 74
ACOG (American College of OB/GYN)	40	Annual (or biennial from 50-74)	Based on health status
NCCN	40	Annual	Life expectancy <10 years
ACR/SBI	40	Annual	Life expectancy <5-7 years

Screening in High-Risk Women

Risk Category	Screening Recommendation	Age to Start
BRCA1/2 mutation	Annual mammogram + annual breast MRI	25-30 (mammo); 25 (MRI)
Strong family history (1+ 1st degree)	Annual mammogram + consider MRI	10 years before youngest affected relative
Lifetime risk >20% (models)	Annual mammogram + annual breast MRI	Determined by specific risk
Prior chest radiation (e.g., Hodgkin)	Annual mammogram + annual breast MRI	8-10 years after radiation or age 25
Prior high-risk lesion (LCIS, ADH, ALH)	Annual mammogram	After diagnosis

Types of Mammography

Type	Details	Advantages
2D digital mammography	Standard digital images	Widely available, good sensitivity
3D digital breast tomosynthesis (DBT)	Multiple image slices reconstructed into 3D	Higher cancer detection (15-40%); fewer recalls; better for dense breasts
Contrast-enhanced mammography (CEM)	IV contrast + mammography	Sensitivity similar to MRI; useful when MRI contraindicated

Breast Density

Density Category (BI-RADS)	Description	Prevalence	Cancer Risk
A (Almost entirely fatty)	<25% glandular tissue	10%	Lowest risk
B (Scattered fibroglandular)	25-50% dense	40%	Intermediate
C (Heterogeneously dense)	51-75% dense	40%	Increased (1.2-2x)
D (Extremely dense)	>75% dense	10%	Highest risk (2-6x)

Dense Breast Notification

State	Status
Dense breast notification laws	Required in 38+ states (as of 2024)
Notification content	Inform of density, recommend supplemental screening discussion
Supplemental screening	Ultrasound (handheld or automated), MRI based on risk

Breast Cancer Risk Factors

Modifiable Risk Factors

Risk Factor	Relative Risk	Mechanism
Alcohol (3+ drinks/day)	1.3-1.5	Increased estrogen levels, DNA damage
Obesity (postmenopausal)	1.3-2	Increased peripheral estrogen conversion
Sedentary lifestyle	1.2-1.5	Metabolic and hormonal effects
Hormone replacement therapy (combined)	1.2-1.75	Estrogen + progestin; risk decreases after discontinuation
Smoking	1.1-1.2	Carcinogens in breast tissue
Night shift work (circadian disruption)	1.1-1.2	Melatonin suppression

Non-Modifiable Risk Factors

Risk Factor	Relative Risk	Notes
Female sex	100+	Breast cancer in men <1% of all
Age >50	Increases with age	2/3 of cancers in women >55
BRCA1 mutation	55-72% lifetime	Triple-negative phenotype
BRCA2 mutation	45-69% lifetime	Hormone receptor positive more common
First-degree relative with breast cancer	1.5-3	2x with one relative; higher with multiple
Personal history of breast cancer	3-4	Second primary risk
Early menarche (<12)	1.2	Longer estrogen exposure
Late menopause (>55)	1.2-1.5	Longer estrogen exposure
Nulliparity	1.2-1.5	No protective effect of pregnancy
First pregnancy after 30	1.2-1.5	Delayed breast maturation
Prior atypical hyperplasia (ADH, ALH, LCIS)	4-10	High-risk marker
Prior chest radiation	3-10	Especially Hodgkin treatment
High breast density (BI-RADS D)	2-6	Both risk and masking

Risk Assessment Models

Model	Factors Included	Best For
Gail Model (BCRAT)	Age, race, age at menarche, age at first birth, family history (1st degree), prior biopsies, atypical hyperplasia	Average-risk women
Tyrer-Cuzick (IBIS)	Extensive family history, including second-degree, male breast cancer, BRCA/genes, density, hormonal factors	Women with family history
BOADICEA	Comprehensive family history, genetic testing	High-risk families
IBIS (International Breast Cancer Intervention Study)	Full risk profile + genetics	Clinical trials

Prevention

Chemoprevention

Agent	Indication	Risk Reduction	Duration	Side Effects
Tamoxifen (SERM)	High-risk premenopausal women (LCIS, ADH, 5-year risk >1.7%)	50% reduction in invasive breast cancer	5 years	Hot flashes, VTE (2-3x), endometrial cancer (2x), cataract
Raloxifene (SERM)	High-risk postmenopausal women	50% reduction in invasive breast cancer	5 years	Hot flashes, VTE (lower than tamoxifen); no endometrial cancer risk
Aromatase inhibitors (exemestane, anastrozole)	High-risk postmenopausal women	50-65% reduction	5 years	Arthralgias, bone loss, fractures
AIs + bisphosphonates	High-risk postmenopausal women with bone loss	As above + bone protection	5 years

Lifestyle Prevention

Intervention	Risk Reduction	Evidence Level
Moderate exercise (150 min/week)	20-30%	Strong
Maintain healthy BMI (18.5-24.9)	10-20%	Strong
Limit alcohol (<1 drink/day)	10-30%	Strong
Breastfeeding (12+ months total)	4% per year	Moderate
Mediterranean diet	6-10%	Moderate
Dietary fiber (25+ g/day)	5-10%	Moderate
Phytoestrogens (soy)	5-10%	Moderate (not harmful post-diagnosis)
Avoid HRT (combined)	Eliminates HRT-attributable risk	Strong

BI-RADS Classification

Category	Assessment	Management
0	Incomplete: additional imaging needed	Additional views, US, MRI
1	Negative: routine screening	Continue routine screening
2	Benign finding	Continue routine screening
3	Probably benign (<2% malignancy)	Short interval follow-up (6 months)
4	Suspicious abnormality (2-95%)	Biopsy indicated
- 4A	Low suspicion (2-10%)	Biopsy
- 4B	Moderate suspicion (10-50%)	Biopsy
- 4C	High suspicion (50-95%)	Biopsy
5	Highly suggestive of malignancy (>95%)	Biopsy and treatment planning
6	Known biopsy-proven malignancy	Definitive treatment